Oral cancers are the sixth most common malignancy worldwide, with low 5-year disease free survival rates, attributable to late detection due to lack of reliable screening modalities. Our in vivo Raman spectroscopy studies have demonstrated classification of normal and tumor as well as cancer field effects (CFE), the earliest events in oral cancers. In view of limitations such as requirement of on-site instrumentation and stringent experimental conditions of this approach, feasibility of classification of normal and cancer using serum was explored using 532 nm excitation. In this study, strong resonance features of β-carotenes, present differentially in normal and pathological conditions, were observed. In the present study, Raman spectra of sera of 36 buccal mucosa, 33 tongue cancers and 17 healthy subjects were recorded using Raman microprobe coupled with 40X objective using 785 nm excitation, a known source of excitation for biomedical applications. To eliminate heterogeneity, average of 3 spectra recorded from each sample was subjected to PC-LDA followed by leave-one-out-cross-validation. Findings indicate average classification efficiency of ~70% for normal and cancer. Buccal mucosa and tongue cancer serum could also be classified with an efficiency of ~68%. Of the two cancers, buccal mucosa cancer and normal could be classified with a higher efficiency. Findings of the study are quite comparable to that of our earlier study, which suggest that there exist significant differences, other than β-carotenes, between normal and cancerous samples which can be exploited for the classification. Prospectively, extensive validation studies will be undertaken to confirm the findings.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.